China - The Next Promised Land For Korean Biosimilars?
Executive Summary
Biosimilar specialists Celltrion and Samsung Bioepis are poised to start competing in China, which they see as another promising market for their biosimilars amid the Chinese government's increasing policy support for biologics and generics, and rising competition elsewhere. Part of their tailored entry approach includes striking deals with local partners.
You may also be interested in...
Chinese Biosimilar Boom Is Heralded By First Approval
Approval of China's first rituximab biosimilar under new pathway gives developers much-needed boost and an opening to the international market for made-in-China biosimilars helped by favorable regulatory policy changes at home.
Biosimilar Boom in China Heralded By First Approval
Approval of China's first rituximab biosimilar under new pathway gives developers much-needed boost and an opening to the international market for made-in-China biosimilars helped by favorable regulatory policy changes at home.
Nine Catalysts For China Biopharma In 2019
After much turmoil in 2018, the biopharma sector in China is embracing multiple uncertainties in the year of the boar.